Company intelligence / Profile preview

Accurant Biotech

Cranbury / Princeton area, New Jersey, United States6sense.com ↗

Ownership: Private
Employees: ~79
Development stage: Other

Overview

Accurant Biotech provides regulated large molecule bioanalytical services supporting over 60 biologics pipelines and 120+ clinical trials. The company notably supported the approval of Carteyva®, the first CAR-T product in China[7][8]. Its US lab passed its first FDA inspection without findings in August 2023[8].

Therapeutic areas: OtherOncologyRare DiseasesHematology
Modalities: Large molecule biologicsCell therapyGene therapy
Industry: Contract Research Organization

Partnerships

No specific major pharma partnerships named publicly. Collaborates with global pharma and biotech companies as clients

Beyond the preview

Go deeper on Accurant Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Accurant Biotech.

Explore the full profile